Following Volcano (NASDAQ:VOLC) has been a frustrating exercise for many years. Despite strong clinical data supporting the company's core IVUS and FFR platforms, the company has struggled to live up to its own growth expectations and management has stubbornly thrown good money after bad with M&A and R&D spending on projects with unclear (at best) paths to management's growth expectations.
Maybe this is the turn. Missing top-line expectations for the sixth time in seven quarters isn't exactly good news, and neither is the present state of stent procedure volume. On the other hand, abandoning the OCT, FL-ICE, FL-IVUS boosts the probability that management is now looking at its real business prospects in a more rational way and may...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|